SER Serina Therapeutics Inc.
Price (delayed)
$5.25
Market cap
$52.14M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.51
Enterprise value
$48.74M
agex therapeutics, inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the united states. the company's lead cell-based therapeutic
Highlights
The equity has surged by 105% since the previous quarter and by 102% year-on-year
The company's debt has shrunk by 98% QoQ and by 92% YoY
The company's EPS has shrunk by 164% YoY but it rose by 31% QoQ
The revenue has dropped by 98% since the previous quarter and by 98% year-on-year
Serina Therapeutics's gross profit has shrunk by 98% QoQ and by 98% YoY
Key stats
What are the main financial stats of SER
Market
Valuations
Earnings
Shares outstanding
9.93M
Market cap
$52.14M
Enterprise value
$48.74M
Price to earnings (P/E)
N/A
Price to book (P/B)
72.83
Price to sales (P/S)
689.91
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
870.36
Revenue
$56,000
Gross profit
$56,000
Operating income
-$17.05M
Net income
-$11.14M
EBIT
-$10.62M
EBITDA
-$10.19M
Free cash flow
-$17.16M
Per share
Balance sheet
Liquidity
EPS
-$1.51
EPS diluted
-$1.51
Free cash flow per share
-$2.33
Book value per share
$0.07
Revenue per share
$0.01
TBVPS
$0.91
Total assets
$6.72M
Total liabilities
$6.22M
Debt
$268,000
Equity
$641,000
Working capital
$3.31M
Debt to equity
0.42
Current ratio
2.4
Quick ratio
1.55
Net debt/EBITDA
0.33
Margins
Efficiency
Dividend
EBITDA margin
-18,203.6%
Gross margin
100%
Net margin
-19,894.6%
Operating margin
-30,442.9%
Return on assets
-124.7%
Return on equity
N/A
Return on invested capital
-992.3%
Return on capital employed
-243.6%
Return on sales
-18,955.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SER stock price
How has the Serina Therapeutics stock price performed over time
Intraday
-4.37%
1 week
-0.76%
1 month
10.29%
1 year
-50%
YTD
4.79%
QTD
-7.41%
Financial performance
How have Serina Therapeutics's revenue and profit performed over time
Revenue
$56,000
Gross profit
$56,000
Operating income
-$17.05M
Net income
-$11.14M
Gross margin
100%
Net margin
-19,894.6%
The revenue has dropped by 98% since the previous quarter and by 98% year-on-year
Serina Therapeutics's gross profit has shrunk by 98% QoQ and by 98% YoY
The company's operating income has shrunk by 51% QoQ
Growth
What is Serina Therapeutics's growth rate over time
Valuation
What is Serina Therapeutics stock price valuation
P/E
N/A
P/B
72.83
P/S
689.91
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
870.36
The company's EPS has shrunk by 164% YoY but it rose by 31% QoQ
The equity has surged by 105% since the previous quarter and by 102% year-on-year
The revenue has dropped by 98% since the previous quarter and by 98% year-on-year
Efficiency
How efficient is Serina Therapeutics business performance
Dividends
What is SER's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SER.
Financial health
How did Serina Therapeutics financials performed over time
Serina Therapeutics's total assets is 8% higher than its total liabilities
The company's total liabilities has shrunk by 71% QoQ but it rose by 28% YoY
The quick ratio has dropped by 71% year-on-year
The company's debt is 58% lower than its equity
The debt to equity has surged by 151% since the previous quarter
The equity has surged by 105% since the previous quarter and by 102% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.